47 Hemoglobin Drop is an Early Predictor of Erythropoietin Supplementation in VHL Syndrome Patients Under Belzutifan Treatment - First Report From The Real-Life BELIEVE-VHL Trial

Jose Claudio Casali-da-Rocha, Caroline Macedo da Silva, Sumin Koh · 2026

Read 47 Hemoglobin Drop is an Early Predictor of Erythropoietin Supplementation in VHL Syndrome Patients Under Belzutifan Treatment - First Report From The Real-Life BELIEVE-VHL Trial by Jose Claudio Casali-da-Rocha, Caroline Macedo da Silva, Sumin Koh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535466.txt.

Description

Jose Claudio Casali-da-Rocha, Caroline Macedo da Silva, and Sumin Koh report early findings in 2026 from a real-life trial of belzutifan in von Hippel-Lindau syndrome. People with this inherited condition grow tumors in the eyes, brain, kidneys, and other organs. The drug blocks a growth factor and works well on those tumors.

Fifty-eight patients joined the trial between late 2023 and late 2025. The team tracked a hormone that drives red blood cell making, plus blood counts, each month for six months. An early drop in blood counts flagged who would later need hormone support. That simple sign could guide safer dosing.

Catalog record

CREATORJose Claudio Casali-da-Rocha, Caroline Macedo da Silva, Sumin Koh
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13535466

Browse the full library · About the Tower of Babel